Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101233 | 0.82 | PKM (0.50) | ALDH1A1KDM4EMAPTNPSR1HSD17B10 | |
| SCHEMBL3828857 | 0.79 | ALDH1A1 (0.80) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL3075649 | 0.75 | CYP2D6 (0.37) | ALDH1A1SMN1; SMN2KDM4ENPSR1HPGD | |
| SCHEMBL2425157 | 0.74 | NR1I2 (0.45) | KMT2AAPOBEC3G | |
| SCHEMBL5138358 | 0.73 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL10953409 | 0.72 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL294183 | 0.72 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL27970004 | 0.70 | ALDH1A1 (0.44) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL8759387 | 0.70 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 | |
| SCHEMBL14247955 | 0.68 | MAPT (0.53) | ALDH1A1SMN1; SMN2KDM4EMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870261-B1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | BIORA THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| EP-4309722-A2 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | Biora Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-4252629-A2 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | Biora Therapeutics, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | BIORA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| EP-3551046-B1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BIORA THERAPEUTICS INC (US) | 2023-07-19 | — | — | EP | disclosed |
| EP-3554541-B1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A CHEMOKINE/CHEMOKINE RECEPTOR INHIBITOR | BIORA THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | GLAS USA LLC | 2023-05-18 | — | — | US | disclosed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115666704-A | Ingestible device for delivery of therapeutic agents to the gastrointestinal tract | 比奥拉治疗股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | GLAS USA LLC | 2023-01-26 | — | — | US | disclosed |
| US-20180168490-A1 | INGESTIBLE DEVICE AND ASSOCIATED METHODS | GLAS USA LLC | 2018-06-21 | — | — | US | disclosed |
| WO-2018106933-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106959-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180164221-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | BT BIDCO LLC | 2018-06-14 | — | — | US | disclosed |
| WO-2018106931-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106945-A1 | GASTROINTESTINAL TRACT DETECTION METHODS, DEVICES AND SYSTEMS | PROGENITY INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20140178367-A1 | Methods of Treating Inflammatory Diseases by Targeting the Chemoattractant Cytokine Receptor 2 (CCR2) or Chemokine (C-C motif) Ligand 2 (CCL2) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8445518-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012138880-A2 | METHODS OF TREATING INFLAMMATORY DISEASES BY TARGETING THE CHEMOATTRACTANT CYTOKINE RECEPTOR 2 (CCR2) OR CHEMOKINE (C-C MOTIF) LIGAND 2 (CCL2) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-7683176-B2 | Triazolyl pyridyl benzenesulfonamides | CHEMOCENTRYX, INC. (US) | 2010-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11707610-B2 | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract | MUC1, SLC10A2, FABP2 | ALDH1A1 2415/4885SMN1; SMN2 426/4885KDM4E 4824/4885 |
| US-20230023414-A1 | METHODS AND DEVICES FOR TREATING A DISEASE WITH BIOTHERAPEUTICS | HAVCR2, CD47, FCGR3B | ALDH1A1 3780/4885SMN1; SMN2 134/4885KDM4E 3948/4885 |
| US-20230149315-A1 | INGESTIBLE DEVICE FOR DELIVERY OF THERAPEUTIC AGENT TO THE GASTROINTESTINAL TRACT | MUC1, SLC10A2, FABP2 | ALDH1A1 2415/4885SMN1; SMN2 426/4885KDM4E 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.